Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan phase 3 study in complement 3 glomerulopathy
NL-OMON60976Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Complement 3 glomerulopathy (C3G) comparing Iptacopan with Placebo (2 arms). Primary endpoints: Proteinuria reduction and Proteinuria reduction at 6 months. Started Mar 2022; status: completed.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NL-OMON60976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60976.